利妥昔单抗在膜性肾病中应用的专家共识  

Expert consensus on the application of rituximab in the treatment of membranous nephropathy

作　　者：北京大学医学部肾脏病学系专家组 赵明辉[2] 于峰[3,4] 崔昭 Nephrology Expert Panel of the Peking University Health Science Center;Zhao Minghui(不详;Renal Division,Department of Medicine,Peking University First Hospital,Institute of Nephrology,Peking University,Key Laboratory of Renal Disease,Ministry of Health of China,Key Laboratory of Chronic Kidney Disease Prevention and Treatment,Ministry of Education of China,Beijing 100034,China)

机构地区：[1]不详 [2]北京大学第一医院肾内科,北京大学肾脏疾病研究所,国家卫生健康委员会肾脏疾病重点实验室,慢性肾脏病防治教育部重点实验室,北京100034 [3]北京大学第一医院肾内科 [4]北京大学国际医院肾内科

出　　处：《中华内科杂志》2022年第3期282-290,共9页Chinese Journal of Internal Medicine

摘　　要：膜性肾病是一种具有不同病因的肾脏疾病病理组织学类型,典型特征为上皮下免疫复合物沉积引起的肾小球基底膜增厚,临床主要表现为肾病综合征或无症状蛋白尿。利妥昔单抗是一种特异性针对B细胞表面抗原CD20的人鼠嵌合型单克隆抗体。近年来,利妥昔单抗逐渐用于膜性肾病的治疗中,取得了良好的疗效。为规范国内利妥昔单抗治疗膜性肾病的临床应用,为临床医生提供实践指导,北京大学医学部肾脏病学系专家组通过检索Pubmed、中国知网数据库、万方数据库和维普数据库等中英文相关医学文献,并结合我国临床诊疗现状,形成本共识。Membranous nephropathy is a histopathological type of renal disease,characterized by the thickening of glomerular basement membrane caused by an accumulation of immune deposits on the outer aspect of the glomerular basement membrane.Its main clinical manifestations are nephrotic syndrome or asymptomatic proteinuria.Rituximab is a murine/human chimeric anti-CD20 monoclonal antibody that depletes B cells.In recent years,rituximab has been applied to the treatment of membranous nephropathy and achieved good effects.The nephrology expert panel of the Peking University Health Science Center formed this consensus by searching PubMed,China National Knowledge Infrastructure database,Wanfang database,VIP database and other relevant literature,and combining the current situation in China,so as to standardize the clinical application of rituximab in the treatment of membranous nephropathy and provide practical guidance for clinicians.

关 键 词：膜性肾病 利妥昔单抗 治疗 共识 

分 类 号：R969[医药卫生—药理学]